SEC Comment Letter 0000000000-22-012677 to OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Nov. 22, 2022 · CIK: 0001849296 · Accession: 0000000000-22-012677
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo November 22, 2022 Gary Jacob, Ph.D. Chief Executive Officer OKYO Pharma Ltd Martello Court Admiral Park, St. Peter Port Guernsey GY1 3HB Re:OKYO Pharma Ltd Draft Registration Statement on Form F-1 Submitted November 17, 2022 CIK No. 0001849296 Dear Gary Jacob: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler, Esq.
Show Raw Text
United States securities and exchange commission logo
November 22, 2022
Gary Jacob, Ph.D.
Chief Executive Officer
OKYO Pharma Ltd
Martello Court
Admiral Park, St. Peter Port
Guernsey GY1 3HB
Re:OKYO Pharma Ltd
Draft Registration Statement on Form F-1
Submitted November 17, 2022
CIK No. 0001849296
Dear Gary Jacob:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler, Esq.